- Home
- IONS
as 11-15-2024 4:00pm EST
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.
| Founded: | 1989 | Country: | United States |
| Employees: | N/A | City: | CARLSBAD |
| Market Cap: | 6.0B | IPO Year: | 1991 |
| Target Price: | $62.00 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Buy | Number of Analysts: | 18 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.46 | EPS Growth: | N/A |
| 52 Week Low/High: | $34.24 - $54.44 | Next Earning Date: | 11-06-2024 |
| Revenue: | $803,067,000 | Revenue Growth: | 30.57% |
| Revenue Growth (this year): | -19.01% | Revenue Growth (next year): | 16.31% |
Stock Insider Trading Activity of Ionis Pharmaceuticals Inc. (IONS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Geary Richard S | IONS | EVP, Chief Development Officer | Aug 28 '24 | Sell | $49.39 | 651 | $32,158.73 | 85,154 |
Latest Ionis Pharmaceuticals Inc. News
IONS Breaking Stock News: Dive into IONS Ticker-Specific Updates for Smart Investing
Simply Wall St.
9 days ago
Ionis Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations
Zacks
10 days ago
Ionis' Q3 Earnings and Revenues Beat Estimates, New Launches in Focus
Zacks
10 days ago
Company News for Nov 7, 2024
PR Newswire
10 days ago
Ionis to present at upcoming investor conferences
Clinical Trials Arena
10 days ago
Ionis announces design for Phase III trial of Angelman syndrome therapy
Thomson Reuters StreetEvents
10 days ago
Q3 2024 Ionis Pharmaceuticals Inc Earnings Call
GuruFocus.com
10 days ago
Ionis Pharmaceuticals Inc (IONS) Q3 2024 Earnings Call Highlights: Navigating Revenue ...
MT Newswires
11 days ago
Ionis Reports Late-Stage Trial Design in Angelman Syndrome
Compare IONS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IONS Ionis Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.